[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Royal Free Hospital NHS Foundation Trust\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":113},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,71,93],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100623897","sleep-disordered-breathing-database-100623897",false,"NCT07402603","Sleep-disordered Breathing Database","Enhancing Patient Care: Sleep and Ventilation Database","Inclusion Criteria:\n\n* Age \\>18 years\n* Referred to Royal Free London NHS Foundation Trust Sleep and Ventilation Service\n* Agreed to undertake a sleep study\n\nExclusion Criteria:\n\n* Inability to consent",true,"ALL","18 Years",{"count":20,"type":21},5000,"ESTIMATED","5 Years","OBSERVATIONAL","The goal of this study is to collect clinical data on patients who have had a sleep study and are given a diagnosis of a sleep related breathing disorder such as obstructive sleep apnoea. Collecting this data in an organised way will mean that the investigators can monitor patients and their health outcomes.",[26,27],"Obstructive Sleep Apnoea (OSA)","Hypoventilation Syndrome",[29,30],"database","observational","NOT_YET_RECRUITING","2026-02-04",{"date":34,"type":35},"2026-02-11","ACTUAL",{"date":37,"type":21},"2026-01-15",{"date":39,"type":21},"2036-01",{"name":41,"class":42},"Royal Free Hospital NHS Foundation Trust","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":43},"100522548","path-active-multicentre-randomised-controlled-trial-previous-pilot-path-active-safety-and-tolerability-study-100522548","NCT06084052","Path Active Multicentre Randomised Controlled Trial (Previous Pilot: Path Active; Safety and Tolerability Study)","PAMRCT","Inclusion Criteria:\n\n* • Participant able to give informed consent.\n* Age \\>18 at the time of consent.\n* Diagnosis of Type 1 or Type 2 Diabetes.\n* Both Feet Intact (no ulceration).\n* Participant understands and is willing to participate and can comply with the follow-up regime.\n* Participant diabetes foot Risk Stratification as 'High Risk' as in Frame (2021) Scotland\u002FEngland https:\u002F\u002Fwww.diabetesframe.org\u002F\n* Ability to walk independently for \\> 100 metres i.e without use of wheelchair, walking stick or personal assistance.\n* Participant able and willing to wear suitable footwear.\n* Must own a mobile phone and be willing to upload WWP app.\n\nExclusion Criteria:\n\n* Either foot has less than 2 arterial vessel run-off on Doppler.\n* Poor visual acuity ie registered blind, unless supported by carer.\n* Current participation in another clinical investigation of a medical device or a drug; or participation in such a study within 30 days prior to study enrolment.\n* Body Mass Index (BMI) \\>40.\n* Participant has bespoke contact insoles and footwear.\n* Participant is unable to use 'medium' or 'large' insoles due to foot size eg. small or extra large feet.\n* Participant has a pacemaker.\n* Participant is pregnant.","100 Years",{"count":53,"type":21},120,"INTERVENTIONAL",[56],"NA","Path Active™ comprises a pair of monitoring insoles which measure parameters associated with foot ulceration in diabetes: temperature and pressure. The insoles are linked via an app to the wearer's mobile phone and also to a clinical dashboard so that both wearer and clinician are alerted to early signs of skin damage on the foot so that immediate preventive action can be taken. The study is a multisite randomised controlled trial which will evaluate the effectiveness of Path Active™ in 60 people with diabetes who are at 'high risk' of foot ulceration, compared with 60 people who receive their usual podiatry foot checks over a period of 12 weeks.",[59],"Diabetic Foot",[61],"Foot Ulcer Prevention","RECRUITING","2025-04-11",{"date":65,"type":35},"2025-04-15",{"date":67,"type":35},"2024-04-02",{"date":69,"type":21},"2026-03-31",{"name":41,"class":42},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":54,"phases":80,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":43},"100571896","walk-and-talk-connecting-people-with-psoriasis-100571896","NCT06726213","Walk and Talk: Connecting People With Psoriasis","'Walk and Talk - Connecting People With Psoriasis'. A Mixed-methods Exploratory Study to Determine Representativeness of Recruitment, Acceptability, and Feasibility of a Walk and Talk Intervention for People With Psoriasis","Inclusion Criteria:\n\n* Aged 18 years or over\n* Diagnosed with psoriasis\n* Currently attending psoriasis services in secondary care\n* Must be able to walk for 30 minutes at a slow pace (approx 2km). Or be a wheelchair user with a carer who can push up hills if necessary\n\nExclusion Criteria:\n\n* Participants who are not capable of understanding the information leaflet or consent form and thus are unable to give informed consent.\n* Participants who do not understand verbal explanations or written information given in English will be excluded, as a number of questionnaires need to be completed. The translation service provided to the hospital is usually telephone operated.\n* Participants not able to walk at a slow pace for 30 minutes will be excluded or wheelchair users who do not have a carer who can help to push up hills.\n* Children will be excluded from study as this study involves making social interactions and contact with adults. This would not be appropriate, as child protection screens will not be performed on participants",{"count":79,"type":21},170,[56],"The main aim of this study is to determine the acceptability, representativeness (e.g. age, sex, ethnicity and body mass index) and ideal format of a Walk and Talk intervention for people with psoriasis.\n\nSecondary aims are determining outcome measures of the intervention (patient related outcome measures, social connectedness, physical activity, cardiovascular risk)\n\nOther objectives are to determine relevant outcome measures and sample size needed to statistically evaluate a future, larger study. There have been no similar studies evaluating social interventions in people with psoriasis, so an exploratory study is needed to calculate how many people are needed to participate. Measures will include social connectedness (loneliness), physical activity, cardiovascular risk, psychological wellbeing, quality of life and psoriasis severity.\n\nPsoriasis is a systemic disease with multiple co-existent health issues. People with psoriasis are more socially isolated and inactive than the general population.\n\nThe health implications of social isolation are now recognised and thought to be equivalent to smoking. Consequently social prescribing is increasingly used for people living with long-term conditions. Specifically group walking activities are effective at increasing physical activity and improving mood. Additionally, disease specific walking groups provide peer psychosocial support.\n\nIt seems likely that a group walking intervention for people with psoriasis could promote social connectedness, increase physical activity and provide peer psychosocial support. However, as people with psoriasis avoid social contact, have low levels of physical activity and difficulty in discussing feelings, it is possible a Walk and Talk activity may not be taken up by many, or only by specific sub-groups such as young, slim, white people. Hence the need for an exploratory study before committing to a larger adequately powered study. Ultimately the investigators anticipate a format for Walk and Talk groups that is specifically tailored for people with psoriasis may enable groups to be rolled out at centres nationwide",[83,84],"Psoriasis","Social Isolation","2024-12-04",{"date":87,"type":35},"2024-12-10",{"date":89,"type":35},"2024-07-07",{"date":91,"type":21},"2026-01",{"name":41,"class":42},{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":43},"100453827","can-waveform-and-flow-traces-from-mechanical-insuflattionexsufflation-mie-be-used-to-identify-laryngeal-responses-to-mie-and-thus-optimise-treatment-algorithms-100453827","NCT05189600","Can Waveform and Flow Traces From Mechanical Insuflattion:Exsufflation (MI:E) be Used to Identify Laryngeal Responses to MI:E and Thus Optimise Treatment Algorithms?","SETTLE","Inclusion Criteria:\n\n* Patients with neuromuscular disease(NMD) including but not limited to Motor Neurone Disease (MND), Multiple Sclerosis (MS) and Muscular Dystrophy\n* Age ≥18\n\nExclusion Criteria:\n\n* Unable to comply with protocol\n* Unable to give informed consent\n* Evidence of obstructive airways disease FEV1:FVC \\\u003C0.7\n* Patients with a history of:\n* Un-drained pneumothorax\n* Severe bronchospasm\n* Head injury with ICP \\> 25mmHg\n* Severe arterial hypotension\n* Trache-oesophageal fistula\n* Significant haemoptysis\n* Facial fractures\n* Vomiting\n* Flail segment\n* Epistaxis within two weeks",{"count":101,"type":21},20,"Objectives:\n\n* To establish if physiotherapists can use the waveform traces from the cough assist machine to work out when patients are having an abnormal airway response to cough assist\n* To establish how cough assist device settings, particularly in breath and cough pressures affect a patient's response to using the cough assist device\n* To provide some clinical guidance to physiotherapists on methods for assessing and treating abnormal airway responses to cough assist devices\n\nMethodology:\n\nSubjects will complete breathing tests; spirometry, peak cough flow (PCF) and sniff nasal inspiratory pressure (SNIP) to establish baseline breathing function and rule out anyone with breathing conditions. A nasal camera will be used to look at the voice box at rest.\n\nCough assist will be delivered via a face mask which will allow for simultaneous use of the nasal camera and cough assist carried out in the same way as another research team have done previously. The nasal camera will be attached to a video camera to allow recording, analysis and documentation of the observations. The cough assist protocol will be delivered by a physiotherapist experienced in delivering cough assist. Cough assist waveforms will be downloaded into Care Orchestrator software (Philips Respironics, Murraysville, USA) and reviewed at the same time as the nose camera recordings to establish if voice box responses can be identified from the waveform patterns. For confirmation of Care Orchestrator software waveforms, a device that records airflow during breathing (spirometer) will be connected (Alpha touch, Vitalograph, Ennis, Ireland) into the cough assist circuit in the same way another research team has before.",[104],"Neuromuscular Diseases","2024-06-12",{"date":107,"type":35},"2024-06-13",{"date":109,"type":35},"2022-01-01",{"date":111,"type":21},"2025-01-01",{"name":41,"class":42},""]